Randomized trial · people

CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes, a large 68-week trial found CagriSema brought clearly more weight loss and better blood sugar than placebo, with stomach and gut side effects common but mostly mild or moderate.

Kind
Randomized trial
Studied in
People
Number studied
1206
Published
2025
Journal
N Engl J Med

What they tested

The team tested whether weekly CagriSema, cagrilintide and semaglutide given together, lowers body weight more than placebo in adults with type 2 diabetes and overweight or obesity.

How the study was done

A phase 3a, double-blind, randomized, placebo-controlled trial in 12 countries enrolled 1206 adults with type 2 diabetes, a body-mass index of 27 or more and an HbA1c (a 3-month average of blood sugar) of 7 to 10%. People were assigned 3:1 to the trial's weekly dose of 2.4 mg of each drug or to placebo (a dummy treatment), both alongside lifestyle changes, for 68 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking CagriSema? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Body weight fell by an estimated 13.7% on CagriSema and 3.4% on placebo by week 68, a difference of 10.4 percentage points. More people on CagriSema than on placebo reached weight loss of at least 5%, 10%, 15% and 20%. An HbA1c of 6.5% or lower was reached by 73.5% of the CagriSema group and 15.9% of the placebo group. Stomach and gut side effects hit 72.5% on CagriSema and 34.4% on placebo, and most were short-lived and mild or moderate.

What it doesn’t show

The trial compared CagriSema only with placebo, so it doesn't show how the pair does against either drug alone, and it ran for 68 weeks in people with type 2 diabetes. It was funded by Novo Nordisk.

The paper

Davies et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025.

The compounds

More studies on CagriSema

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking CagriSema? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo